| Document Date: 2014-09-09 11:11:56
Open Document File Size: 345,56 KBShare Result on Facebook
City Reference / / Company Ames / Allergan / / Event FDA Phase / Product Issues / Person Communication and Meetings / / IndustryTerm ophthalmic solution / sterile ophthalmic solution / chemical name / excess solution / chemical structure / topical ophthalmic products / / MedicalCondition photophobia / active intraocular inflammation / cystoid macular edema / Intraocular Inflammation LATISSE / asthenopia / hypotrichosis / Macular Edema / headaches / conjunctival hyperemia / superficial punctate keratitis / ocular irritation / Intraocular Inflammation / Carcinogenesis / Neither nevi / Serious infections / periorbital erythema / bacterial keratitis / local allergic reactions / allergic conjunctivitis / eye pruritus / conjunctivitis / ocular infections / eye pain / Macular Edema Macular edema / iritis / hypersensitivity / infection / ocular hypertension / inflammation / alopecia areata / freckles / infections / rash / skin hyperpigmentation / cataract / upper respiratory tract infections / blepharitis / uveitis / / MedicalTreatment chemotherapy / surgery / / Organization WARNINGS AND PRECAUTIONS___________ Concurrent administration / DOSAGE AND ADMINISTRATION / FDA / / Person Iris Darkening / / / Position Counsel / physician / representative / / Product sodium chloride / LUMIGAN / solutions / S-008 / PATIENT INFORMATION LATISSE® / applicator / / Technology Pharmacokinetics / chemotherapy / / URL www.fda.gov/medwatch / /
SocialTag |
NDA[removed]S-008 NDA[removed]S-010 Page 5 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed